Scarica l'app Stockscreener
14.18
5.34%
-0.80
Dopo l'orario di chiusura:
14.35
0.17
+1.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Peregrine Capital Management LLC Boosts Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics Included in Forbes America’s Best Employers 2025 List - GlobeNewswire
This Healthcare Giant's Employee Satisfaction Rate Crushes Industry Average by 27% - StockTitan
Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 - GlobeNewswire
Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research - GlobeNewswire Inc.
Myriad Genetics Sets Stage for Major Q4 Financial Reveal: 3 Key Investor Conferences Follow - StockTitan
Myriad Genetics (NASDAQ:MYGN) Trading 8.3% HigherHere's What Happened - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Myriad Genetics secures patents for cancer MRD tests - MSN
Insiders Sold US$6.5m Of Myriad Genetics Stock Possibly Sending Warning Sign - Simply Wall St
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Genomic Biomarker Market Projected To Witness Substantial Growth, 2025-2032: Myriad Genetics, Inc., Eurofins - EIN News
PARP Inhibitor Biomarkers Market Top Players- Myriad Genetics, - openPR
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts - Benzinga
Craig-Hallum initiates Myriad Genetics stock with a Buy rating By Investing.com - Investing.com South Africa
MYGN Stock Might Rise on Collaboration With CancerCARE - MSN
Jennison Associates LLC Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing - Nasdaq
Myriad Genetics and CancerCARE for Life Announce Agreement - GlobeNewswire
Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients - StockTitan
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewswire
Predictive Genetic Counselling Market Size, Trends, - openPR
Myriad Genetics and Lumea Collaborate to Enhance Access to - GlobeNewswire
Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay -February 05, 2025 at 05:41 pm EST - Marketscreener.com
Myriad Genetics secures patents for cancer MRD tests By Investing.com - Investing.com South Africa
Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay - Marketscreener.com
Myriad Genetics Partners With Lumea To Integrate Prolaris And MyRisk Tests Into BxLink Platform - Nasdaq
Myriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink - Nasdaq
Lumea and Myriad Genetics Collaborate to Enhance Access to Biomarker and Hereditary Cancer Tests in BxLink - EIN News
Pancreatic Cancer Market Size USD 5.7 Billion, Opportunities, - openPR
Blue Trust Inc. Boosts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Piper Sandler Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $14.00 - MarketBeat
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World
Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat
Myriad Genetics Unveils Award-Winning Research on Early Prenatal Screening Technology at SMFM Conference - Nasdaq
Myriad Genetics Unveils Groundbreaking Eight Weeks’ - GlobeNewswire
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
0.06%
3.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):